Skip to content

Analysis of related factors of clinical efficacy of aspirin in the treatment of recurrent abortion

Analysis of related factors of clinical efficacy of aspirin in the treatment of recurrent abortion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092513
Enrollment
Unknown
Registered
2024-11-18
Start date
2024-11-20
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent spontaneous abortion

Interventions

aspirin resistance:Not applicable
Aspirin sensitivity:Not applicable

Sponsors

Fujian Maternity and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Recurrent abortion patients with antiphospholipid antibody positive treated with aspirin; (2) Antithrombotic therapy lasts for at least 2 weeks.

Exclusion criteria

Exclusion criteria: (1) Women with a definite diagnosis of anatomic genital abnormality by ultrasound or hysterosalpingography; (2) couples or embryos have chromosomal abnormalities; (3) Women with a history of taking teratogenic drugs in early pregnancy; (4) Women with a history of gastrointestinal surgery, severe digestive disease, or liver disease; (5) Women with renal insufficiency, history of coronary heart disease, heart disease, malignancy or diseases of the blood or immune system; (6) Women with reproductive tract infections; (7) Incomplete data information.

Design outcomes

Primary

MeasureTime frame
Live birth;

Secondary

MeasureTime frame
Platelet aggregation function;Minor bleeding;

Countries

China

Contacts

Public ContactJinhua Zhang

Fujian Maternity and Child Health Hospita

pollyzhang2006@126.com+86 133 0691 2381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026